CRNX
NASDAQCrinetics Pharmaceuticals Inc.
Price$83.83+0.01 (+0.01%)
01:30 PM07:45 PM
News · 26 weeks64+200%
2026-01-182026-07-12
Mix3490d
- SEC Filings11(32%)
- Insider10(29%)
- Other8(24%)
- Earnings3(9%)
- Leadership1(3%)
- Analyst1(3%)
Latest news
25 items- SECSEC Form DEFA14A filed by Crinetics Pharmaceuticals Inc.DEFA14A - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
- SECCrinetics Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Entry into a Material Definitive Agreement8-K - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
- INSIDERDirector Vivaldi Coelho Rogerio sold $120,000 worth of shares (3,000 units at $40.00) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 19,225 units (SEC Form 4)4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
- SECSEC Form DEFA14A filed by Crinetics Pharmaceuticals Inc.DEFA14A - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
- SECSEC Form DEFA14A filed by Crinetics Pharmaceuticals Inc.DEFA14A - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
- SECSEC Form 8-K filed by Crinetics Pharmaceuticals Inc.8-K - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
- PRVertex to Acquire Crinetics Pharmaceuticals- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated ther
- SECSEC Form 144 filed by Crinetics Pharmaceuticals Inc.144 - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)
- ANALYSTUBS initiated coverage on Crinetics Pharmaceuticals with a new price targetUBS initiated coverage of Crinetics Pharmaceuticals with a rating of Buy and set a new price target of $55.00
- PRCrinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 4, 2026SAN DIEGO, June 30, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that it will report second quarter 2026 financial results on Tuesday, August 4, 2026 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Tuesday, August 4 at 4:30 p.m. ET Domestic:1 833-461-5787International:1 585-542-9983Meeting ID:758613006Passcode:214866 Webcast: Participants can use the dial-in numbers above OR access the live webcast via a direct link (HERE) or by visiting the Events section of the Crinetics website. To ensure a timely connection, it is re
- INSIDERDirector Deardorf Caren was granted 5,925 shares, increasing direct ownership by 36% to 22,225 units (SEC Form 4)4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
- INSIDERDirector Fust Matthew K was granted 5,925 shares, increasing direct ownership by 26% to 28,761 units (SEC Form 4)4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
- INSIDERDirector Nichols Weston was granted 5,925 shares, increasing direct ownership by 36% to 22,225 units (SEC Form 4)4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
- INSIDERDirector Vivaldi Coelho Rogerio was granted 5,925 shares, increasing direct ownership by 36% to 22,225 units (SEC Form 4)4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
- INSIDERDirector Bedrosian Camille L was granted 5,925 shares, increasing direct ownership by 36% to 22,225 units (SEC Form 4)4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
- INSIDERDirector Wierenga Wendell was granted 5,925 shares, increasing direct ownership by 5% to 122,071 units (SEC Form 4)4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
- INSIDERDirector Okey Stephanie was granted 5,925 shares, increasing direct ownership by 93% to 12,325 units (SEC Form 4)4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
- SECSEC Form 8-K filed by Crinetics Pharmaceuticals Inc.8-K - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
- INSIDERDirector Okey Stephanie sold $246,143 worth of shares (6,900 units at $35.67) as part of a pre-agreed trading plan, decreasing direct ownership by 52% to 6,400 units (SEC Form 4)4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
- PRCrinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026Data show investigational atumelnant drove sustained androgen reductions while enabling lowering of glucocorticoid supplementation to physiologically normal levels in adults with classic CAH New results from the Phase 1b/2a ACTH-dependent Cushing's syndrome trial also presented, showing atumelnant rapidly lowered early morning cortisol and normalized urinary free cortisol levels even at lower dose SAN DIEGO, June 14, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) presented data today from the open-label, Phase 2 congenital adrenal hyperplasia (CAH) adult study of investigational atumelnant, a novel, once-daily oral adrenocorticotropic hormone (ACTH) receptor antag
- PRCrinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly ControlData from up to two years of treatment in PATHFNDR-1 and PATHFNDR-2 open-label extension studies show PALSONIFY maintained lower IGF-1 levels and stable symptoms Treatment also resulted in stable or reduced pituitary tumor volumes for up to 48 weeks Additional ENDO highlights include long-term ACROBAT data demonstrating PALSONIFY and cabergoline combination improves biochemical control of acromegaly SAN DIEGO, June 14, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced new long-term data from its clinical development program evaluating novel PALSONIFYTM (paltusotine) in acromegaly during an oral presentation at the Endocrine Society's Annual Meeting,
- PRCrinetics and Leading Patient Groups Launch 'Everyday Advocacy' Initiative to Empower People Across Endocrine Disease CommunitiesEveryday Advocacy provides people living with endocrine and endocrine-related conditions with education, support, and tools to facilitate more impactful healthcare team interactions Steering committee of five leading patient organizations to guide program with authentic perspectives and insights into most significant patient needs SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced the launch of Everyday Advocacy, a new initiative designed to support patient education, self-advocacy, and connection within endocrine disease communities. "Crinetics is led by a conviction that meaningful progress for endocrine disease treatment begins
- INSIDERPresident & CEO Struthers Richard Scott gifted 968,800 shares and received a gift of 968,800 shares (SEC Form 4)4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
- PRCrinetics' Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six PresentationsOral presentation features open label extension PALSONIFY™ (paltusotine) data, reinforcing its best-in-class potential in acromegaly following recent U.S. and E.U. approvals Two oral presentations of novel, investigational ACTH receptor antagonist atumelnant include full Phase 2 study results in congenital adrenal hyperplasia and data from additional patients in the Phase 1b/2a ACTH-dependent Cushing's syndrome study SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that data from six abstracts, including oral presentations featuring PALSONIFY™ (paltusotine) and investigational candidate atumelnant, will be presented at t
- PRCrinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026SAN DIEGO, May 22, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), today announced that company management will participate in the Jefferies Global Healthcare Conference, taking place June 2-4, 2026 in New York, NY. Management will be available for 1x1 meetings with investors on Wednesday, June 3, 2026. If you are interested in arranging a 1x1 meeting with management, please contact your conference representative. ABOUT CRINETICS PHARMACEUTICALS Crinetics Pharmaceuticals is a global pharmaceutical company committed to transforming the treatment of endocrine diseases and endocrine-related tumors through science rooted in patient needs. Crinetics is focused on dis
CRNX FAQ
7 questionsWhat does Crinetics Pharmaceuticals Inc. do?
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 biased agonist that has completed phase II clinical trial for the treatment of acromegaly, as well as completed phase 1 clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide...Where does CRNX stock trade?
Crinetics Pharmaceuticals Inc. (CRNX) is listed on NASDAQ.What sector and industry is CRNX in?
Crinetics Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Crinetics Pharmaceuticals Inc. go public?
Crinetics Pharmaceuticals Inc. (CRNX) completed its IPO in 2018.What are analysts saying about CRNX?
Crinetics Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from UBS: Buy on 2026-07-02. Recent price targets cluster around $3600.00.What companies are similar to CRNX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare CRNX side-by-side with any of them on Quantisnow.How can I track CRNX on Quantisnow?
Quantisnow aggregates Crinetics Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CRNX to receive live email and push alerts on every new disclosure.